Opendata, web and dolomites

ViR SIGNED

We are developing ground-breaking therapeutics to cure currently untreatable respiratory infections affecting children and the elderly

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ViR" data sheet

The following table provides information about the project.

Coordinator
VIRELIEVE THERAPEUTICS 

Organization address
address: 29 RUE DES SORBIERS
city: COGNIN LES GORGES
postcode: 38470
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.virelieve.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2019-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VIRELIEVE THERAPEUTICS FR (COGNIN LES GORGES) coordinator 50˙000.00

Map

 Project objective

Human respiratory viruses cause economic and health burdens worldwide because there are no effective therapies. We have discovered a novel approach to stop their infection. The human respiratory viruses parainfluenza (PIV) and respiratory syncytial (RSV) viruses cause economic and health burdens worldwide. While RSV is the number one cause of death in children under 5 years old, with over 33M new cases occurring annually worldwide, PIV is the cause of 4-5% of all respiratory infections and 6-11% of all hospitalizations. However, currently there are no effective therapeutics to treat these debilitating infections and the economic burden associated with RSV and PIV is estimated at more than $11B annually, also defining a multi-billion dollar pharmaceutical market gap. We founded ViRelieve - biotech company with the main purpose to develop much-needed therapeutics to treat infections caused by RSV, PIV and related viruses. ViRelieve is led by an experienced team with biotech business, finance and IP expertise, drug development experience from pharmaceutical companies, and top researchers in virology and chemistry. We have discovered weaknesses in two processes essential for the virus infection – virus entry and replication, and have developed novel approaches to block these processes and thus stop these viruses from causing disease. Our R&D program has led to several patents filed and issued for unique compounds that specifically target essential virus components and demonstrated their effectiveness in animal models. Thus, our therapeutics will specifically treat RSV and PIV infections and will be superior to the few existing solutions as well as future competitors. In summary, gathering a complete expert team, filling patents, securing exclusive licenses and demonstrating the efficiency of our innovative therapeutics in animals makes us uniquely poised to succeed in our venture to deliver efficient drug candidates to clinical trials in a timely and effective manner.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VIR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VIR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Presque (2019)

Smart Nursing Bra

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More